AU2017366870B2 - A pharmaceutical composition for averting opioid addiction - Google Patents

A pharmaceutical composition for averting opioid addiction Download PDF

Info

Publication number
AU2017366870B2
AU2017366870B2 AU2017366870A AU2017366870A AU2017366870B2 AU 2017366870 B2 AU2017366870 B2 AU 2017366870B2 AU 2017366870 A AU2017366870 A AU 2017366870A AU 2017366870 A AU2017366870 A AU 2017366870A AU 2017366870 B2 AU2017366870 B2 AU 2017366870B2
Authority
AU
Australia
Prior art keywords
patient
antibody
pain
week
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017366870A
Other languages
English (en)
Other versions
AU2017366870A1 (en
Inventor
John Davis
Catherine Stehman-Breen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2017366870A1 publication Critical patent/AU2017366870A1/en
Application granted granted Critical
Publication of AU2017366870B2 publication Critical patent/AU2017366870B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2017366870A 2016-11-29 2017-11-28 A pharmaceutical composition for averting opioid addiction Active AU2017366870B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662427365P 2016-11-29 2016-11-29
US62/427,365 2016-11-29
PCT/US2017/063417 WO2018102294A1 (en) 2016-11-29 2017-11-28 A pharmaceutical composition for averting opioid addiction

Publications (2)

Publication Number Publication Date
AU2017366870A1 AU2017366870A1 (en) 2019-06-06
AU2017366870B2 true AU2017366870B2 (en) 2024-09-19

Family

ID=60766150

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017366870A Active AU2017366870B2 (en) 2016-11-29 2017-11-28 A pharmaceutical composition for averting opioid addiction

Country Status (18)

Country Link
US (2) US10736961B2 (cg-RX-API-DMAC7.html)
EP (1) EP3548082B1 (cg-RX-API-DMAC7.html)
JP (1) JP7071975B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190090820A (cg-RX-API-DMAC7.html)
CN (1) CN110072549A (cg-RX-API-DMAC7.html)
AU (1) AU2017366870B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019010331A2 (cg-RX-API-DMAC7.html)
CA (1) CA3045116A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001385A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019005247A2 (cg-RX-API-DMAC7.html)
EA (1) EA201991283A9 (cg-RX-API-DMAC7.html)
IL (1) IL266640B (cg-RX-API-DMAC7.html)
MA (2) MA45890B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019006013A (cg-RX-API-DMAC7.html)
MY (1) MY200701A (cg-RX-API-DMAC7.html)
PH (1) PH12019501087A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018102294A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201902967B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210043624A (ko) * 2018-08-10 2021-04-21 리제너론 파아마슈티컬스, 인크. 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물
EP4433500A1 (en) 2021-11-19 2024-09-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
EP4514849A1 (en) 2022-04-27 2025-03-05 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
SI2263692T1 (sl) 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
US7988967B2 (en) * 2007-08-10 2011-08-02 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
PH12013500672A1 (en) 2010-10-06 2013-06-03 Regeneron Pharma Stabilized formulations containing anti-interleukin-4-receptor (il-4r) antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHANG DS ET AL: "Anti-nerve growth factor in pain management: current evidence", JOURNAL OF PAIN RESEARCH, 1 June 2016 (2016-06-01), Vol. 8, No. 9, pages 373-83, XP055441926, DOI: 10.2147/JPR.S89061 *
KIVITZ ALAN J ET AL: PAIN, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 154, no. 7, 14 March 2013 (2013-03-14), pages 1009 - 1021, XP028561837, ISSN: 0304-3959, DOI: 10.1016/J.PAIN.2013.03.006 *
TISEO PAUL J ET AL: PAIN, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 155, no. 7, 29 March 2014 (2014-03-29), pages 1245 - 1252, XP029006342, ISSN: 0304-3959, DOI: 10.1016/J.PAIN.2014.03.018 *
TISEO PJ ET AL: JOURNAL OF PAIN RESEARCH, 22 August 2014, Vol. 7, pages 523-530, DOI: 10.2147/JPR.S65974 *

Also Published As

Publication number Publication date
MA46951A (fr) 2019-10-09
EA201991283A1 (ru) 2019-09-30
JP7071975B2 (ja) 2022-05-19
WO2018102294A1 (en) 2018-06-07
CO2019005247A2 (es) 2019-05-31
EP3548082B1 (en) 2024-05-15
US10736961B2 (en) 2020-08-11
AU2017366870A1 (en) 2019-06-06
IL266640B (en) 2022-09-01
US11491222B2 (en) 2022-11-08
BR112019010331A2 (pt) 2019-10-22
MA45890B2 (fr) 2022-10-31
MY200701A (en) 2024-01-11
EP3548082A1 (en) 2019-10-09
EA201991283A9 (ru) 2019-11-27
MX2019006013A (es) 2019-10-14
PH12019501087A1 (en) 2019-08-19
MA45890A1 (fr) 2020-02-28
CN110072549A (zh) 2019-07-30
ZA201902967B (en) 2024-10-30
CL2019001385A1 (es) 2019-07-26
US20210060159A1 (en) 2021-03-04
IL266640A (en) 2019-07-31
JP2019535716A (ja) 2019-12-12
KR20190090820A (ko) 2019-08-02
US20180147280A1 (en) 2018-05-31
CA3045116A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
JP7736667B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
KR102122708B1 (ko) Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
JP7745529B2 (ja) 関節リウマチを処置するための組成物及び方法
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
US11491222B2 (en) Method of treating lower back pain
US20220041708A1 (en) Pharmaceutical Composition for Safe and Effective Treatment of Knee and/or Hip Pain
KR20210122810A (ko) 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
US20250011408A1 (en) Methods and compositions for reducing centralized pain
RU2786232C2 (ru) Фармацевтическая композиция для безопасного и эффективного лечения боли колена и/или тазобедренного сустава
US20240002491A1 (en) Methods for selecting patients for treatment with an ngf antagonist
EA044062B1 (ru) Фармацевтическая композиция для предотвращения опиоидной зависимости
HK40011843A (en) A pharmaceutical composition for averting opioid addiction
KR20200069388A (ko) Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
JP2023506732A (ja) ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)